Bacterial lipopolysaccharide as negative predictor of gemcitabine efficacy in advanced pancreatic cancer – translational results from the AIO-PK0104 phase 3 study

Michael Guenther, Michael Haas, Volker Heinemann, Stephan Kruger, Christoph Benedikt Westphalen, Michael von Bergwelt-Baildon, Julia Mayerle, Jens Werner, Thomas Kirchner, Stefan Boeck, Steffen Ormanns
doi: https://doi.org/10.1101/2020.05.01.20087668

Article usage

Article usage: May 2020 to November 2024

AbstractFullPdf
May 2020267093
Jun 202062026
Jul 202062026
Aug 202057023
Sep 202052029
Oct 202033029
Nov 20202209
Dec 202027012
Jan 202139118
Feb 20213916
Mar 20215516
Apr 20215625
May 20215535
Jun 20215627
Jul 20212738
Aug 20212269
Sep 20211838
Oct 202116019
Nov 202118218
Dec 20212103
Jan 20221556
Feb 20221400
Mar 20221904
Apr 20221223
May 20221108
Jun 20221423
Jul 20221101
Aug 20221623
Sep 202228011
Oct 20222018
Nov 2022917
Dec 20221314
Jan 20231504
Feb 20231024
Mar 2023600
Apr 20231814
May 20231247
Jun 2023441
Jul 2023504
Aug 202314134
Sep 20231455
Oct 2023805
Nov 2023801
Dec 2023910
Jan 2024302
Feb 2024611
Mar 2024713
Apr 2024984
May 20241024
Jun 2024933
Jul 20241112
Aug 2024512
Sep 20241036
Oct 20241265
Nov 2024637
Back to top
Posted May 06, 2020.
Download PDF

Supplementary Material

Data/Code
Email
Bacterial lipopolysaccharide as negative predictor of gemcitabine efficacy in advanced pancreatic cancer – translational results from the AIO-PK0104 phase 3 study
Michael Guenther, Michael Haas, Volker Heinemann, Stephan Kruger, Christoph Benedikt Westphalen, Michael von Bergwelt-Baildon, Julia Mayerle, Jens Werner, Thomas Kirchner, Stefan Boeck, Steffen Ormanns
medRxiv 2020.05.01.20087668; doi: https://doi.org/10.1101/2020.05.01.20087668
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area